NCT00776750

Influenza Vaccination in Hemodialysis Patients and Renal Transplant Recipients

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 407 (actual)
• Sponsor: Universitaire Ziekenhuizen KU Leuven · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

Disturbances of acquired immunity are considered to be responsible, at least partly, for the high infection rate and inadequate response to vaccinations observed in hemodialysis (HD) patients and renal transplant recipient (RTR). The present prospective trial aims at (a) evaluating the immunogenicity of a standard influenza vaccine in HD and RTR patients and (b) at identifying determinants of the immune response.

Conditions

• Hemodialysis
• Renal Transplantation

Interventions

Type	Name	Description
BIOLOGICAL	trivalent split influenza vaccine	standard dose of 0.5 ml commercially available trivalent split influenza vaccine (Vaxigrip®, Aventis Pasteur MSD) by intramuscular injection

Timeline

• Start date: 2003-09-01
• Primary completion: 2004-05-01
• Completion: 2004-05-01
• First posted: 2008-10-21
• Last updated: 2008-10-21

Locations

1 site across 1 country: Belgium